What are the side effects of Avatrombopag?

In clinical studies of Avatrombopag, the most common adverse reactions reported by at least 3% of patients were fever, abdominal pain, nausea, headache, fatigue and peripheral edema. Hyponatremia was also a rare serious side effect of the drug. Adverse reactions leading to discontinuation include anemia, pyrexia, and myalgia. After avatrombopag was marketed, adverse events including allergic reactions including pruritus, rash, choking sensation, erythema, pharyngeal edema, general itching, macules, facial swelling, and tongue swelling also occurred.

Because avatrombopag is a thrombopoietin (TPO) receptor agonist, TPO receptor agonists have been associated with thrombotic and thromboembolic complications in patients with chronic liver disease. Portal vein thrombosis has been reported in patients with chronic liver disease receiving TPO receptor agonists. There are currently no known antidotes for overdose, and hemodialysis is not expected to enhance the clearance of avatropopag because only approximately 6% of avatropopag is excreted by the kidneys and is highly bound to plasma proteins. If a patient requires treatment with avatrombopag, physicians should closely monitor the patient and their platelet count.

The original drug of avatrombopag has been launched in China and has entered the scope of Class B medical insurance, but it is only reimbursed for eligible patients. The price of a common specification of 20mg*15 tablets may be more than 7,000 yuan per box, while the original drug of avatrombopag marketed overseas is even more expensive. It is understood that there are generic drugs of avatrombopag available overseas, and their pharmaceutical ingredients are basically the same as those of the original drug. For example, the price of a box of 20mg*30 tablets in Laos pharmaceutical production specifications may be around RMB 1,000 (the price may fluctuate due to exchange rates).